Jefferies raises Viridian Therapeutic stock price target on trial data By Investing.com

Jefferies raised Viridian Therapeutics to a $28 price target from $25 while keeping a Buy rating, implying about 53% upside from the $18.27 share price. The note follows positive REVEAL-2 Phase 3 data for subcutaneous elegrobart in chronic thyroid eye disease, with 50% and 54% proptosis responder rates versus 15% for placebo. Offset by competitive pressure from Amgen/Tepezza and mixed analyst views, the stock remains supported by a Strong Buy consensus and targets ranging from $20 to $50.

Analysis

VRDN is increasingly a “category bifurcation” story rather than a simple single-asset readout. If the chronic TED population is as underserved as the market implies, the commercial prize is less about peak efficacy parity and more about tolerability, dosing convenience, and physician willingness to move earlier in treatment—areas where a subcutaneous regimen can matter disproportionately. That creates a credible path to a premium franchise even if the drug never fully matches the incumbent’s headline response rate, because the addressable segment is likely to expand as the treatment burden falls.

The harder second-order question is competitive response: the largest risk is not another biotech entrant, but the incumbent’s ability to defend with formulation, dosing, or access tactics that compress differentiation before VRDN builds habit. If payers view the market as interchangeable efficacy with incremental convenience, pricing pressure could arrive quickly and cap the implied upside. Conversely, if chronic TED adoption is driven by specialist preference and patient persistence, the loser is not just the incumbent but also adjacent ophthalmology practices that rely on infusion-center economics.

On timing, this is a months-long catalyst path, not a days-only trade. The stock’s drawdown suggests expectations are still fragile, which is useful if subsequent data or payer commentary confirms that chronic-use adoption is the real unlock; but the setup can reverse sharply on any signal that competitive efficacy remains the gating issue. The market is probably underpricing how much of the valuation is now tied to commercial execution rather than binary clinical success.

Contrarian view: the move may be over-discounting the idea that subcutaneous convenience can substitute for efficacy leadership. In a specialist market, physicians often anchor first on response rate and only second on route of administration, so the path to broad uptake may be slower than the bullish model assumes. That makes this more attractive as a staged position than a full-size event-driven bet.

Key Decisions for Investors

• Initiate a tactical long VRDN on weakness over the next 1-2 weeks, sized for a 3-6 month catalyst horizon; target a 25-35% rebound if payer/launch messaging validates chronic-TED differentiation, with a stop if follow-up commentary suggests efficacy is still the primary barrier.
• Pair trade: long VRDN / short AMGN as a relative-value expression over 2-4 months; the thesis is not absolute upside for VRDN, but that chronic-TED convenience can re-rate faster than the incumbent’s mature franchise, with downside capped if the market stops viewing the products as fully substitutable.
• Use call spreads instead of common for VRDN into the next catalyst window: buy 3-6 month calls with strikes near current analyst consensus targets and finance via an out-of-the-money short call to express upside while limiting theta if commercialization proof takes longer.
• Fade the rally in AMGN only if subsequent market share commentary shows no pricing defense; otherwise avoid outright shorting the incumbent, since access and prescriber inertia can preserve its cash flows even if VRDN wins mindshare.
• Set a decision point after the next management update: add to VRDN only if adoption metrics imply specialist conversion, not just positive trial language; if not, treat the name as a trading vehicle rather than a core long.